Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody

von Staflin, Karin, Zuch de Zafra, Christina L., Schutt, Leah K., Clark, Vanessa, Zhong, Fiona, Hristopoulos, Maria, Clark, Robyn, Li, Ji, Mathieu, Mary, Chen, Xiaocheng, Johnston, Jennifer, Low, Justin, Ybarra, Ryan, Slaga, Dionysos, Yang, Jihong, Ovacik, Meric, Dybdal, Noël O., Totpal, Klara, Junttila, Melissa R., Ellerman, Diego, Lee, Genee, Dennis, Mark S., Prell, Rodney, Junttila, Teemu T.
Veröffentlicht in JCI Insight (2020)